Did You Know...
...that after Walter Hunt patented the safety pin in 1849, he sold the rights to it for $400?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7384640 | Mutant cholera holotoxin as an adjuvant A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an adjuvant in an antigenic composition to enhance the immune response in a... | 06/10/2008 |
| 7364745 | Development of a live, attenuated, recombinant vaccine for Brucellosis A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure... | 04/29/2008 |
| 7118739 | Biocontrol of plant diseases caused by species with novel isolates of Microbiological agents are provided for control of certain diseases of wheat and other cereals caused by Fusarium species, including Fusarium head blight of wheat and other cereals. These agents can also improve yield of wheat plants and cereals. The a... | 10/10/2006 |
| 7041296 | Methods of treating inflammatory bowel disease using cholera toxin B subunit The present invention provides a method of treating or preventing inflammation in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. The present invention also provides a method of decreasing the activity of interferon... | 05/09/2006 |
| 6991793 | Method of protecting fish against columnaris disease with modified live Safe and effective live vaccines against Flavobacterium columnare of fish were created through the induction of rifampicin resistance in a native Flavobacterium columnare isolate; these including rifampicin-resistant mutants NRRL B-30303 and B-30304. S... | 01/31/2006 |
| 6942861 | Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability The present invention describes the isolation and purification of histidine-tagged functional portions of intimin (his-tagged intimin or his-intimin), a protein associated with the ability of certain strains of pathogenic bacteria to adhere to epithelial cells. The ... | 09/13/2005 |
| 6811787 | Over-expressing homologous antigen vaccine and a method of making the same This invention relates to an over-expressing homologous antigen vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an ... | 11/02/2004 |
| 6605696 | Lawsonia intracellularis proteins, and related methods and materials Isolated polynucleotide molecules contain a nucleotide sequence that encodes a L. intracellularis HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein, a substantial portion of the sequences, or a homologous sequence. Related polypeptides, immunogenic co... | 08/12/2003 |
| 6599509 | Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease The treatment of IBD in mammals, including humans, is described. More particularly, the present invention relates to compositions and methods for the treatment of IBD associated with Helicobacter or other bacterial infections in mammals, including humans,... | 07/29/2003 |
| 6582699 | Combination vaccine for enhancing immunity against brucellosis A vaccine comprising a combination of Brucella "A" and "M" outer-polysaccharides (OPSs) and "R" protein antigens for enhancing immunity against brucellosis is disclosed. The OPS may be obtained from different strains or species of Brucellae (i.e. combinin... | 06/24/2003 |
| 6444210 | Bacterial and synthetic polysaccharide immunomodulators that enhance general immunity The present invention relates to the effects of bacterial polysaccharides on cell mediated immunity in animals. Polysaccharides of the present invention comprise the outer polysaccharides (OPS) located on bacterial cell membranes and other polysaccharides... | 09/03/2002 |
| 6444445 | Live vaccine against Brucellosis Live Brucella vaccines and methods for preparing the live vaccines protective against brucellosis are described. The vaccines are prepared by introducing a deletion in the rfbU gene of a strain of Brucella which results in attenuation of the strain while ... | 09/03/2002 |
| 6436652 | Method of detecting a pathogen using a virus A bacteriophage linked to an enzyme can replace an antibody in a system for detecting the presence of a bacteria in a sample. Specifically Brucella abortus (a pathogen which causes brucellosis in cattle) can be detected using Brucella bacteriophage for th... | 08/20/2002 |
| 6296855 | 17-KDA Brucella abortus antigen, recombinant polypeptides, nucleic acids coding for the same and use thereof in diagnostic and prophylactic methods and kits The present invention relates to an isolated 17-kDa Brucclla antigen characterized by an amino acid sequence having at least 60% homology, preferably at least 70% homology, more preferably having at least 80% homology to the amino acid sequence as shown i... | 10/02/2001 |
| 6277379 | Use of purified invaplex from gram negative bacteria as a vaccine A novel composition comprising Invaplex from gram-negative bacteria is described and is effective as a vaccine against gram-negative bacterial infection.... | 08/21/2001 |
| 6221386 | Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents Liposome encapsulated antibiotic therapy has limited application against infectious organisms, which can sequester in non-phagocytic cells. Virulence factors of these infectious organisms, for example bacterial components, when used in the formulation of ... | 04/24/2001 |
| 6203799 | Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit V. cholerae vaccine strains which have a soft agar penetration-defective phenotype and methods for making such strains are described. Also described are methods for identifying new genes involved in V. cholerae motility and the cloning, identification, an... | 03/20/2001 |
| 6149920 | Over-expressing homologous antigen vaccine and a method of making the same This invention relates to an over-expressing homologous antigen vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vac... | 11/21/2000 |
| 5997881 | Method of making non-pyrogenic lipopolysaccharide or A The present invention provides gram-negative bacterial strains that produce substantially pure non-pyrogenic lipopolysaccharide or lipid A. The present invention also relates to a use of said strains for the preparation of non-pyrogenic DNA and use of the... | 12/07/1999 |
| 5951987 | Polysaccharide vaccine to enhance immunity against brucellosis A vaccine comprising purified outer-polysaccharide (OPS) is effective for protection against brucellosis. The vaccine is derived from Brucella or a variety of cross reactive bacteria. The vaccine can be administered by different routes (intramuscularly, s... | 09/14/1999 |
| 5939075 | Mutants of Brucella melitensis The vaccines are prepared by isolating the Brucella genes complementing mutations in the purEK genes of Escherichia coli, physically mapping, determining the DNA sequence, constructing a defined deletion mutation by polynucleotide chain reaction (PCR), in... | 08/17/1999 |
| 5906826 | Method of inducing an immune response in a young animal The invention provides a method of priming an immune response in the presence of maternal antibody in a young animal by administering to a 1-90 day old animal, a biocompatible and non-toxic solid phase implant containing an immunogenic agent. A preferred ... | 05/25/1999 |
| 5858352 | Vaccine containing a Shigella bacterium having an enhanced antigenic property Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced bacteria for use in vaccines. Also disclosed are methods for usi... | 01/12/1999 |
| 5855894 | Pasteurella haemolytica type A-1 bacterin-toxoid vaccine This invention relates to the field of Pasteurella haemolytica vaccines. More particularly, the invention relates to a bacterin-toxoid vaccine capable of inducing immunity in bovine species in one dose against Pasteurella haemolytica Type A-1 infection co... | 01/05/1999 |
| 5804199 | Oil-based and water-based adjuvant mixture The invention relates to a vaccine comprising an antigenic substance and a mixture of two adjuvants wherein one adjuvant is oil-based whereas the other adjuvant is water-based.... | 09/08/1998 |
| 5718903 | Vaccine comprising Brucella abortus which has O polysaccharide antigen absent The present invention is an improved vaccine against Brucella abortus which permits differentiation between vaccinated and field strain infected cattle. The vaccine can be administered in two different forms: (1) cell envelopes isolated from an O polysacc... | 02/17/1998 |
| 5006463 | Immunoassays for discriminating between brucellosis infections and vaccinations A method is disclosed for discriminating between cattle vaccinated against and those infected with Brucella spp. The method involves immunoassay using a purified polysaccharide containing 4,6-dideoxy-4-acylamido-D-mannopyranosyl units obtained from B. abo... | 04/09/1991 |
| 4764370 | Vaccine utilizing an avirulent strain of Salmonella typhimurium A vaccine against a microbial pathogen comprised of a live, immunogenic but prototrophic and avirulent mutant strain of the selected microbial pathogen in an amount effective to confer immunity. A method of obtaining a vaccine that induces a heightened ce... | 08/16/1988 |
| 4701323 | Vaccines for counteracting inhibition of neutrophil degranulation Vaccines for counteracting inhibition of neutrophil degranulation by pathogenic cellular microorganisms comprise one or more purines conjugated to antigenic carriers. The purines include adenine and/or guanine in the form of a base, nucleoside, or nucleot... | 10/20/1987 |
| 4493825 | Purified and antigenically selective vaccines for domestic animals Purified antigenically selective vaccines for domestic animals are prepared from microorganism cultures containing the immunizing agent by first complexing the immunizing agent with micro-particles having bound IgG antibodies specific for the immunizing a... | 01/15/1985 |
| 4340588 | Brucellosis vaccine for cattle containing mycolate esters of trehalose Vaccine utilizing killed Brucella abortus strain 45/20 whole cells is useful for immunizing bovines. The vaccine contains trehalose dimycolate or an analog as an adjuvant.... | 07/20/1982 |
| 4152412 | Marking vaccine A vaccine, toxoid or like agent is administered to an animal by injecting the agent (usually intracutaneously) on a physiologically acceptable colored particle, preferably activated charcoal, which has a particle size whereby the colored particle remains ... | 05/01/1979 |
